| (Values in U.S. Thousands) | Jul, 2025 | Apr, 2025 | Jan, 2025 | Jul, 2024 | Apr, 2024 |
| Sales | 0 | 0 | 0 | 0 | 1 |
| Sales Growth | unch | unch | -100.00% | -93.19% | -65.71% |
| Net Income | -84 | -52 | -107 | 154 | -82 |
| Net Income Growth | -60.64% | +51.54% | -169.66% | +287.38% | +4.39% |
Genix Pharmaceuticals Corp (GENX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically, the company operates only in Canada.
Fiscal Year End Date: 10/31